Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Sirolimus

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.https://marketing.lgmpharma.com/LGM-CDMO

    Virtual Booth

    Contact Supplier

    Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    RAP

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 114,628Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Palvella Therapeutics Announces Positive SELVA Results for QTORIN
    Palvella Therapeutics Announces Positive SELVA Results for QTORIN

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243306/0/en/Palvella-Therapeutics-Announces-Positive-Topline-Results-from-Phase-3-SELVA-Clinical-Study-of-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-in-Microcystic-Lymphatic-Malformat.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Palvella Hosts SELVA Call on QTORIN for Lymphatic Malformations
    Palvella Hosts SELVA Call on QTORIN for Lymphatic Malformations

    23 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/23/3243093/0/en/Palvella-Therapeutics-to-Host-Conference-Call-to-Discuss-Topline-Results-from-Phase-3-SELVA-Clinical-Trial-of-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-in-Microcystic-Lym.html

    GLOBENEWSWIRE
    23 Feb 2026
    Share Share
    FDA Fast-Tracks Palvella's QTORIN for Angiokeratomas
    FDA Fast-Tracks Palvella's QTORIN for Angiokeratomas

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206115/0/en/Palvella-Therapeutics-Granted-FDA-Fast-Track-Designation-for-QTORIN-3-9-Rapamycin-Anhydrous-Gel-QTORIN-rapamycin-for-the-Treatment-of-Angiokeratomas.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Sarepta to Test Elevidys with Immunosuppressive Regimen
    Sarepta to Test Elevidys with Immunosuppressive Regimen

    26 Nov 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251125916203/en/Sarepta-Announces-Approval-to-Begin-ENDEAVOR-Cohort-8-to-Evaluate-Enhanced-Immunosuppression-Regimen-as-Part-of-ELEVIDYS-Gene-Therapy-for-Non-Ambulant-Individuals-with-Duchenne

    BUSINESSWIRE
    26 Nov 2025
    Share Share
    Quoin Hits Target Loadings For Two Topical Rapamycin Platforms
    Quoin Hits Target Loadings For Two Topical Rapamycin Platforms

    11 Nov 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/11/11/3185408/0/en/Quoin-Pharmaceuticals-Announces-Achievement-of-Topical-Rapamycin-Target-Loadings-for-Two-Proprietary-Delivery-Technologies.html

    GLOBENEWSWIRE
    11 Nov 2025
    Share Share
    Orchestra BioMed Enrolls First Patients in Virtue SAB US Trial
    Orchestra BioMed Enrolls First Patients in Virtue SAB US Trial

    27 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/27/3174623/0/en/Orchestra-BioMed-Announces-First-Patients-Enrolled-in-Virtue-SAB-US-Pivotal-IDE-Coronary-Trial.html

    GLOBENEWSWIRE
    27 Oct 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.